{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:23:33Z","timestamp":1787757813543,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>ABSTRACT<\/jats:title>\n                    <jats:p>Transcatheter aortic valve replacement (TAVR) is a treatment option for patients with asymptomatic severe aortic stenosis who are candidates for a bioprosthesis across the entire spectrum of risk. TAVR carries a risk for thrombotic and bleeding events, focusing on the importance of defining the optimal antithrombotic regimen. Patients undergoing TAVR are mostly elderly and have many comorbidities such as atrial fibrillation (AF) requiring oral anticoagulants (OACs) or coronary artery disease requiring antiplatelet agents. After TAVR among patients without baseline indications for OAC, recent data suggest dual-antiplatelet therapy is associated with an increased risk for bleeding events, particularly early postprocedure compared with single-antiplatelet therapy with aspirin. The risk of leaflet thrombosis in patients undergoing TAVR raised concern about the use of OAC in patients without an initial indication for anticoagulation therapy. Although it showed effectiveness in modulating thrombus formation at the valve level, the bleeding hazard has shown to be unacceptably high, and the net benefit of combining antiplatelet and OAC therapy is unproven. For patients with indications for the use of long-term OAC, such as those with AF, adding antiplatelet therapy increases bleeding events. A favorable effect of new OAC agents over Vitamin K antagonists is debatable. Overall, single-antiplatelet therapy and OAC appear to be reasonable strategies in patients without and with indications for concurrent anticoagulation, respectively. This article aims to review the available published studies and recommendations in the literature regarding the use of antithrombotic therapy post-TAVR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/heartviews.heartviews_36_22","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T05:12:39Z","timestamp":1652677959000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Antithrombotic Therapy after Transcatheter Aortic Valve Replacement"],"prefix":"10.4103","volume":"23","author":[{"given":"Tariq A. M.","family":"Mousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazar","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240902","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","article-title":"Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: A consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease","volume":"42","author":"Ten Berg","year":"2021","journal-title":"Eur Heart J"},{"key":"R2-2-20240902","first-page":"e35","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"R3-2-20240902","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"R4-2-20240902","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-2-20240902","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-2-20240902","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-2-20240902","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.amjcard.2019.01.049","article-title":"Usefulness of clopidogrel loading in patients who underwent transcatheter aortic valve implantation (from the BRAVO-3 randomized trial)","volume":"123","author":"Nijenhuis","year":"2019","journal-title":"Am J Cardiol"},{"key":"R8-2-20240902","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jcin.2020.09.062","article-title":"Safety and efficacy of transcatheter aortic valve replacement with continuation of vitamin K antagonists or direct oral anticoagulants","volume":"14","author":"Brinkert","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R9-2-20240902","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R10-2-20240902","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2018.03.008","article-title":"Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial","volume":"200","author":"Collet","year":"2018","journal-title":"Am Heart J"},{"key":"R11-2-20240902","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: The ARTE (Aspirin Versus Aspirin+Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R12-2-20240902","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"R13-2-20240902","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ehjcvp\/pvz064","article-title":"Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation","volume":"7","author":"Butt","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R14-2-20240902","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes after transcatheter aortic valve replacement","volume":"12","author":"Jochheim","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"R15-2-20240902","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jcin.2016.06.025","article-title":"Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement","volume":"9","author":"Abdul-Jawad Altisent","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R16-2-20240902","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"R17-2-20240902","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.jacc.2020.04.043","article-title":"Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy","volume":"75","author":"Makkar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R18-2-20240902","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"ENVISAGE-TAVI AF Investigators. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Heart Views"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_36_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:54:02Z","timestamp":1787756042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/heartviews.heartviews_36_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/heartviews.heartviews_36_22","relation":{},"ISSN":["1995-705X"],"issn-type":[{"value":"1995-705X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}